JAMA AUGUST 04, 2020

Effect of Vitamin D3 Supplementation on Development of Depression or Clinically Relevant Depressive Symptoms in Older Adults: The VITAL-DEP Randomized Clinical Trial

Olivia I. Okereke, et al.

Bottom Line

In this large, long-term randomized clinical trial, daily supplementation with 2000 IU of vitamin D3 did not significantly reduce the risk of developing incident or recurrent depression or improve mood scores in older adults compared to placebo.

Key Findings

1. The study found no statistically significant difference in the primary composite endpoint (incident or recurrent depression or clinically relevant depressive symptoms) between the vitamin D3 group and the placebo group (hazard ratio 0.97; 95% CI, 0.87-1.09; P = .62).

2. Over a median follow-up of 5.3 years, 609 participants in the vitamin D3 group (6.6%) and 625 participants in the placebo group (6.8%) developed the primary depression outcome.

3. There were no significant differences between the treatment groups in terms of changes in mood scores over time as measured by the 8-item Patient Health Questionnaire (PHQ-8).

4. Prespecified subgroup analyses, including by age, sex, race, and baseline history of depression, showed no significant effect modification by vitamin D3 supplementation.

Study Design

Design

RCT

Double-Blind

Sample

18,353

Patients

Duration

5.3 yr

Median

Setting

Multicenter, US

Population Men aged 50 years or older and women aged 55 years or older without clinically relevant depressive symptoms at baseline.

Intervention Daily supplementation with 2000 IU of vitamin D3 (cholecalciferol).

Comparator Matching placebo.

Outcome A composite endpoint of incident or recurrent depression (defined as clinical diagnosis, initiation of antidepressant treatment, or PHQ-8 score ≥10) and mean change in mood scores over time.

Study Limitations

• The study included a general population of older adults without specific requirements for vitamin D deficiency, potentially diluting any therapeutic effect in those with baseline low levels.

• The reliance on self-reported clinical diagnoses, medication use, and symptom questionnaires for defining depression may have resulted in some misclassification of events.

• The findings may not be generalizable to younger populations or those with severe clinical depression, as the study focused on primary prevention in mid-to-late life.

Clinical Significance

These results do not support the routine use of high-dose vitamin D3 supplements for the primary prevention of depression in the general older adult population, despite observational data suggesting a link between low vitamin D levels and depressive symptoms.

Historical Context

Observational studies and smaller trials have long hypothesized that vitamin D deficiency may contribute to the pathophysiology of depression. VITAL-DEP was designed as an ancillary study to the nationwide VITAL trial to provide a rigorous, large-scale investigation to address these unanswered questions regarding the role of vitamin D in mental health prevention.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the physiological basis for the hypothesized link between vitamin D and depression, and why might observational studies suggest a benefit that randomized clinical trials (RCTs) like VITAL-DEP fail to confirm?

Key Response

Vitamin D receptors (VDR) are distributed in brain regions involved in mood regulation, such as the prefrontal cortex and hippocampus. While observational studies often show a correlation between low serum 25(OH)D levels and depression, this is frequently confounded by 'reverse causality'—depressed individuals may spend less time outdoors or have poorer diets—rather than vitamin D deficiency causing the mood disorder. RCTs like VITAL-DEP provide higher-quality evidence by isolating the intervention from these lifestyle confounders.

Resident

A 70-year-old patient with no history of depression asks if they should start taking 2000 IU of Vitamin D3 daily specifically to preserve their mental health and prevent 'late-life blues.' Based on the results of the VITAL-DEP trial, how should you counsel this patient?

Key Response

The resident should counsel the patient that according to the VITAL-DEP trial, which followed over 18,000 adults for a median of 5.3 years, daily vitamin D3 supplementation did not reduce the risk of developing depression or improve overall mood scores compared to placebo. The patient should be advised that while Vitamin D is important for bone health, it is not currently indicated for the prevention of depression or for enhancing mood in the general older adult population.

Fellow

VITAL-DEP primarily evaluated the prevention of incident depression. To what extent do these findings apply to the 'treatment' of patients with active Major Depressive Disorder (MDD) and co-morbid severe vitamin D deficiency?

Key Response

VITAL-DEP was a prevention trial in a largely vitamin-D-sufficient population (mean baseline 25(OH)D was ~31 ng/mL). Therefore, the results cannot be extrapolated to the treatment of active clinical MDD, particularly in patients with severe deficiency (<10-12 ng/mL). Fellows must distinguish between 'prevention in a healthy population' and 'adjunctive treatment in a symptomatic, deficient population,' where small-scale studies have occasionally suggested some benefit.

Attending

Considering the null results of VITAL-DEP alongside the broader VITAL trial results (which showed no significant reduction in major CV events or total cancer), how does this trial influence the clinical teaching of 'de-prescribing' and the 'can’t hurt, might help' philosophy in geriatric medicine?

Key Response

This trial is a high-yield teaching point for evidence-based de-prescribing. It challenges the 'low-risk' justification for universal supplementation. Attending physicians can use this to teach that every unnecessary supplement increases pill burden, cost, and potential for pharmacy-related errors in older adults. The trial reinforces that supplements should be treated as medications with specific indications rather than general 'wellness' tonics.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Evaluate the impact of the 'threshold effect' and baseline nutrient status on the statistical power and interpretability of the VITAL-DEP trial. How does the inclusion of vitamin-D-sufficient individuals affect the likelihood of a Type II error?

Key Response

Nutritional interventions often exhibit a threshold effect where benefits are only seen when correcting a deficiency. Because the mean baseline 25(OH)D level in VITAL-DEP was already above 30 ng/mL, the study may have been 'functionally' underpowered to detect an effect that only exists in the deficient range. PhD researchers must consider whether the trial truly tested the biological hypothesis or merely the effects of 'extra' vitamin D in an already sufficient cohort.

Journal Editor

As a reviewer, how would you address the potential for 'contamination' in the VITAL-DEP study, where participants in the placebo group may have been taking outside vitamin D supplements, and how does this affect the study’s internal validity?

Key Response

In long-term large-scale trials, placebo group contamination (participants taking their own vitamin D) is a common threat to validity. Editors would look at the protocol's allowance for outside supplements (VITAL allowed up to 800 IU/day). If the placebo group's vitamin D levels rose significantly over time, the 'delta' between groups shrinks, potentially masking a true effect. However, VITAL-DEP's large sample size and high adherence rates typically mitigate this, making the null result more robust.

Guideline Committee

Should the VITAL-DEP results prompt a revision of current USPSTF or APA guidelines regarding the screening of Vitamin D in psychiatric populations or the use of supplements for mood stabilization?

Key Response

Current USPSTF guidelines find insufficient evidence for screening for vitamin D deficiency in asymptomatic adults, and APA guidelines do not list vitamin D as a standard-of-care prophylactic for depression. VITAL-DEP provides high-level (Level 1) evidence that supports 'not' recommending vitamin D for the prevention of depression. This trial reinforces existing conservative guidelines and provides a strong evidence base to resist pressure to add vitamin D to primary care mental health bundles for older adults.

Clinical Landscape

Noteworthy Related Trials

2017

ViDA Study

n = 5,108 · Lancet Diabetes Endocrinol

Tested

Vitamin D3 100,000 IU monthly

Population

Adults aged 50-84 years in New Zealand

Comparator

Placebo

Endpoint

Cardiovascular disease incidence

Key result: Monthly vitamin D3 supplementation did not prevent cardiovascular disease or other major health outcomes in a broad population.

2019

VITAL Trial

n = 25,871 · NEJM

Tested

Vitamin D3 2000 IU daily plus Omega-3 fatty acids

Population

Men >=50 and women >=55 without prior cancer or CV disease

Comparator

Placebo

Endpoint

Major cardiovascular events and invasive cancer incidence

Key result: Vitamin D supplementation did not result in a lower incidence of invasive cancer or cardiovascular events compared to placebo.

2022

D-Health Trial

n = 21,315 · Lancet Diabetes Endocrinol

Tested

Vitamin D3 60,000 IU monthly

Population

Community-dwelling adults aged 60-84 years

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Vitamin D supplementation did not reduce the risk of all-cause mortality, cancer, or cardiovascular disease in the general older population.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis